Calliditas Q1 report, January - March 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2024
0mins
Should l Buy ?
Source: PRnewswire
- Target Market Expansion: Calliditas Therapeutics AB has achieved full approval in the US, leading to plans for target market expansion.
- Q1 Performance: The company reported a record quarter in Q1 2024 with high demand, 705 enrollments, and 354 new prescribers.
- Outlook for 2024: Calliditas expects continued revenue growth, estimating total net sales from the Nefecon franchise to be USD 150-180 million by December 31, 2024.
- Investor Presentation: An investor presentation is scheduled for May 23, 2024, at 14:30 CET, with details available for participation via webcast or conference call registration.
- Contact Information: For further information, individuals can reach out to Åsa Hillsten, Head of IR & Sustainability at Calliditas, through provided contact details.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
